Clinical Trials Directory

Trials / Unknown

UnknownNCT02290561

SmartTarget THERAPY

SmartTarget - A Magnetic Resonance Image to Ultrasound Fusion System for Targeted Prostate Intervention: Therapy

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
69 (estimated)
Sponsor
University College, London · Academic / Other
Sex
Male
Age
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess how accurately SmartTarget can direct high intensity focused ultrasound (HIFU) to a pre-defined area (cancer) in the prostate. The current standard methods for treating prostate cancer are directed to the whole gland - either surgery to remove it or radiotherapy. An alternative method is focal therapy. This is surgery that uses an energy source to ablate the cancer whilst preserving the normal healthy tissue. Prior to surgery prostate cancer can often be localised using MRI imaging and detailed prostate biopsy techniques. The difficulty is that during surgery it is very difficult to accurately locate the cancer on the live ultrasound images - to compensate surgeons will treat half or a quarter of the prostate to ensure that the cancer is treated. This may cause higher rates of side-effects. SmartTarget is an MRI to ultrasound fusion device that maps the pre-treatment MRI onto the live ultrasound during surgery. It then provides a target for the surgeons to treat during the operation. The results will measure if the area intended to treat was covered and if how accurate the treatment was by comparing the pre-treatment MRI with a 1 week post treatment scan

Conditions

Interventions

TypeNameDescription
PROCEDURESmartTarget TherapyMRI to Ultrasound fusion directed HIFU
DEVICEMRI
DEVICEhigh intensity focused ultrasound (HIFU)

Timeline

Start date
2014-12-01
Primary completion
2015-10-01
Completion
2015-10-01
First posted
2014-11-14
Last updated
2014-11-14

Source: ClinicalTrials.gov record NCT02290561. Inclusion in this directory is not an endorsement.